Yixintang Pharmaceutical Group Management
Management criteria checks 4/4
Yixintang Pharmaceutical Group's CEO is Yong Zhang, appointed in Nov 2019, has a tenure of 5.5 years. directly owns 0.055% of the company’s shares, worth CN¥4.37M. The average tenure of the management team and the board of directors is 5.5 years and 5.5 years respectively.
Key information
Yong Zhang
Chief executive officer
CN¥860.0k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 5.5yrs |
| CEO ownership | 0.05% |
| Management average tenure | 5.5yrs |
| Board average tenure | 5.5yrs |
Recent management updates
Recent updates
Yixintang Pharmaceutical Group (SZSE:002727) Has A Pretty Healthy Balance Sheet
Mar 21
Calculating The Fair Value Of Yixintang Pharmaceutical Group Co., Ltd. (SZSE:002727)
Dec 12Yixintang Pharmaceutical Group (SZSE:002727) Might Be Having Difficulty Using Its Capital Effectively
Nov 22Yixintang Pharmaceutical Group's (SZSE:002727) Soft Earnings Are Actually Better Than They Appear
Nov 06Market Cool On Yixintang Pharmaceutical Group Co., Ltd.'s (SZSE:002727) Earnings
Sep 25These 4 Measures Indicate That Yixintang Pharmaceutical Group (SZSE:002727) Is Using Debt Reasonably Well
Jul 15Some Investors May Be Worried About Yixintang Pharmaceutical Group's (SZSE:002727) Returns On Capital
Jun 29Yixintang Pharmaceutical Group Co., Ltd.'s (SZSE:002727) Intrinsic Value Is Potentially 26% Below Its Share Price
Jun 13Market Cool On Yixintang Pharmaceutical Group Co., Ltd.'s (SZSE:002727) Earnings Pushing Shares 27% Lower
Jun 13Yixintang Pharmaceutical Group (SZSE:002727) Is Due To Pay A Dividend Of CN¥0.40
May 27Yixintang Pharmaceutical Group's (SZSE:002727) Conservative Accounting Might Explain Soft Earnings
May 03Investors Holding Back On Yixintang Pharmaceutical Group Co., Ltd. (SZSE:002727)
Apr 15Return Trends At Yixintang Pharmaceutical Group (SZSE:002727) Aren't Appealing
Mar 06CEO
Yong Zhang (46 yo)
5.5yrs
Tenure
CN¥860,000
Compensation
Mr. Yong Zhang serves as Executive Director at Yixintang Pharmaceutical Group Co., Ltd. since November 18, 2019 and serves as its Executive President.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President & Executive Chairman | 11.5yrs | CN¥1.00m | 31.74% CN¥ 2.5b | |
| Executive President & Executive Director | 5.5yrs | CN¥860.00k | 0.055% CN¥ 4.4m | |
| Financial Manager | no data | CN¥35.00k | 0.011% CN¥ 899.2k | |
| Executive Director & Vice President | 5.5yrs | CN¥860.00k | 0.051% CN¥ 4.0m | |
| VP & Secretary | 5.5yrs | CN¥500.00k | 0.033% CN¥ 2.7m |
5.5yrs
Average Tenure
46yo
Average Age
Experienced Management: 002727's management team is seasoned and experienced (5.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President & Executive Chairman | 11.5yrs | CN¥1.00m | 31.74% CN¥ 2.5b | |
| Executive President & Executive Director | 5.5yrs | CN¥860.00k | 0.055% CN¥ 4.4m | |
| Executive Director & Vice President | 5.5yrs | CN¥860.00k | 0.051% CN¥ 4.0m | |
| Non-Independent Director | 11.5yrs | CN¥100.80k | 11.76% CN¥ 935.6m | |
| Non-Independent Director | 8.5yrs | CN¥860.00k | 0.051% CN¥ 4.0m | |
| Independent Director | 5.5yrs | CN¥120.00k | no data | |
| Non-Employee Supervisor | 5.5yrs | no data | no data | |
| Independent Director | 5.5yrs | CN¥120.00k | no data | |
| Non-Independent Director | 7yrs | no data | no data | |
| Independent Director | 5.5yrs | CN¥120.00k | no data | |
| Chairman of the Supervisory Board | 5.5yrs | no data | no data | |
| Supervisor | 5.5yrs | no data | no data |
5.5yrs
Average Tenure
55yo
Average Age
Experienced Board: 002727's board of directors are considered experienced (5.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/14 00:23 |
| End of Day Share Price | 2025/05/14 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Yixintang Pharmaceutical Group Co., Ltd. is covered by 16 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Haigang Chen | China International Capital Corporation Limited |
| Zhu Chen | Citic Securities Co., Ltd. |
| Yonglin Yan | CLSA |